Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation-Reference-Cited by-同舟云学术

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation

Published:2018-11-02 Issue:7 Volume:54 Page:1077-1081
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Sidiqi M. Hasib,Aljama Mohammed A.,Muchtar Eli^ORCID,Buadi Francis K.,Warsame Rahma,Lacy Martha Q.,Dispenzieri Angela,Dingli David,Leung Nelson^ORCID,Gonsalves Wilson I.,Kapoor Prashant,Kourelis Taxiarchis V.,Hogan William J.^ORCID,Wolf Robert C.,Kumar Shaji K.^ORCID,Gertz Morie A.

Funder

Spectrum Pharmaceuticals, Inc., Irvine, CA, USA

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0388-x.pdf

Reference12 articles.

1. Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731–5.

2. Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100:2607–12.

3. Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:344–56.